These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36210235)

  • 21. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
    Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
    Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment.
    Bonanno S; Cavalcante P; Salvi E; Giagnorio E; Malacarne C; Cattaneo M; Andreetta F; Venerando A; Pensato V; Gellera C; Zanin R; Arnoldi MT; Dosi C; Mantegazza R; Masson R; Maggi L; Marcuzzo S
    Front Cell Neurosci; 2022; 16():982760. PubMed ID: 36035258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
    Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
    J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen.
    Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J
    J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac function evaluation in children with spinal muscular atrophy: A case-control study.
    He X; Li X; Yan M; Peng H; Zhang L; Liang Y; Tang W; Li S
    Pediatr Int; 2024; 66(1):e15769. PubMed ID: 38742693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NFL is a marker of treatment response in children with SMA treated with nusinersen.
    Olsson B; Alberg L; Cullen NC; Michael E; Wahlgren L; Kroksmark AK; Rostasy K; Blennow K; Zetterberg H; Tulinius M
    J Neurol; 2019 Sep; 266(9):2129-2136. PubMed ID: 31123861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples.
    Welby E; Rehborg RJ; Harmelink M; Ebert AD
    Hum Mol Genet; 2022 Jun; 31(11):1830-1843. PubMed ID: 34919695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review.
    Gavriilaki M; Papaliagkas V; Stamperna A; Moschou M; Notas K; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
    Acta Neurol Belg; 2023 Oct; 123(5):1735-1745. PubMed ID: 35861914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen.
    Andrés-Benito P; Vázquez-Costa JF; Ñungo Garzón NC; Colomina MJ; Marco C; González L; Terrafeta C; Domínguez R; Ferrer I; Povedano M
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Steinbach M; Blaschek A; Baumann M; Baumgartner M; Becker B; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Küpper H; Johannsen J; Kamm C; Koch JC; Köhler C; Kölbel H; Kolzter K; von Moers A; Naegel S; Neuwirth C; Petri S; Rödiger A; Schimmel M; Schrank B; Schreiber G; Smitka M; Stadler C; Steiner E; Stögmann E; Trollmann R; Türk M; Weiler M; Stoltenburg C; Willichowsky E; Zeller D; Ziegler A; Lochmüller H; Kirschner J;
    J Neuromuscul Dis; 2023; 10(1):29-40. PubMed ID: 36565133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 40. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.
    Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.